Drug class
Diagnostic radiopharmaceutical; PSMA-targeted fluorine-18 PET imaging agent
Mechanism of action
A urea-based ligand binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. The fluorine-18 positron-emitting radionuclide enables PET visualisation of PSMA-expressing lesions.
General use cases
- PET imaging of PSMA-positive lesions in men with prostate cancer when metastatic disease is suspected in candidates for initial definitive therapy or recurrence is suspected due to elevated PSA.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
